Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367412 | 0.86 | ALDH1A1 (0.34) | SLC18A3ALDH1A1LMNAPTGS2ELANE | |
| SCHEMBL16367319 | 0.83 | POLB (0.36) | POLBMAPTTHRBKMT2APTGS2 | |
| SCHEMBL16367365 | 0.79 | MMP2 (0.36) | POLBMAPTTHRBALDH1A1LMNA | |
| SCHEMBL16367310 | 0.78 | POLB (0.37) | SLC18A3POLBMAPTTHRBALDH1A1 | |
| SCHEMBL16367391 | 0.77 | KMT2A (0.38) | SLC18A3ALDH1A1KMT2AKDM4EELANE | |
| SCHEMBL16367379 | 0.76 | MAPK1 (0.35) | ALDH1A1KMT2AKDM4EELANEMAPK1 | |
| SCHEMBL15607848 | 0.75 | PTGS2 (0.31) | PTGS2 | |
| SCHEMBL16367357 | 0.72 | MAPK1 (0.60) | MAPTTHRBALDH1A1LMNAKMT2A | |
| SCHEMBL15607856 | 0.71 | MAPK1 (0.34) | ALDH1A1KMT2AKDM4EELANEMAPK1 | |
| SCHEMBL16367348 | 0.71 | DHODH (0.34) | MAPTALDH1A1LMNAKMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | SLC18A3 2208/4885POLB 1684/4885MAPT 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.